Azenta, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US1143401024
USD
35.10
-0.05 (-0.14%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Azenta, Inc. stock-summary
stock-summary
Azenta, Inc.
Pharmaceuticals & Biotechnology
Brooks Automation, Inc. is a provider of automation solutions for various applications and markets. The Company operates through two segments: Brooks Semiconductor Solutions Group and Brooks Life Science Systems. The Brooks Semiconductor Solutions Group segment offers critical automated transport, vacuum and contamination control solutions and services. Its product offerings include robots and integrated automation systems for handling of substrates. It also offers equipment for automated contamination control, conditioning and metrology solutions for wafer and reticle carriers. The Brooks Life Science Systems segment offers sample life cycle management solutions that provide life science and bioscience customers with a range of sample management solutions for scientific research and support drug development.
Company Coordinates stock-summary
Company Details
15 Elizabeth Dr , CHELMSFORD MA : 01824-4111
stock-summary
Tel: 1 978 26224001 978 2622635
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 87 Schemes (65.72%)

Foreign Institutions

Held by 134 Foreign Institutions (15.91%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Joseph Martin
Independent Chairman of the Board
Dr. Stephen Schwartz
President, Chief Executive Officer, Director
Ms. Robyn Davis
Independent Director
Ms. Erica McLaughlin
Independent Director
Prof. Dr. Krishna Palepu
Independent Director
Mr. Kirk Pond
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
144 Million
(Quarterly Results - Jun 2025)
Net Profit:
1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,748 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.19

stock-summary
Return on Equity

-1.07%

stock-summary
Price to Book

1.04